212 related articles for article (PubMed ID: 23846570)
1. Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
Gupta-Wright A; Wood R; Bekker LG; Lawn SD
J Acquir Immune Defic Syndr; 2013 Nov; 64(3):261-70. PubMed ID: 23846570
[TBL] [Abstract][Full Text] [Related]
2. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa.
Gupta A; Wood R; Kaplan R; Bekker LG; Lawn SD
PLoS One; 2013; 8(2):e55824. PubMed ID: 23418463
[TBL] [Abstract][Full Text] [Related]
3. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
Teasdale CA; Sogaula N; Yuengling KA; Wang C; Mutiti A; Arpadi S; Nxele M; Pepeta L; Mogashoa M; Rivadeneira ED; Abrams EJ
J Int AIDS Soc; 2018 Aug; 21(8):e25168. PubMed ID: 30094952
[TBL] [Abstract][Full Text] [Related]
4. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.
Lawn SD; Myer L; Edwards D; Bekker LG; Wood R
AIDS; 2009 Aug; 23(13):1717-25. PubMed ID: 19461502
[TBL] [Abstract][Full Text] [Related]
5. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
Shoko C; Chikobvu D; Bessong PO
S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
[TBL] [Abstract][Full Text] [Related]
6. Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade.
Wolday D; Kebede Y; Legesse D; Siraj DS; McBride JA; Kirsch MJ; Striker R
PLoS One; 2020; 15(5):e0233049. PubMed ID: 32442166
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
Shet A; Kumarasamy N; Poongulali S; Shastri S; Kumar DS; Rewari BB; Arumugam K; Antony J; De Costa A; D'Souza G
Curr HIV Res; 2016; 14(1):71-9. PubMed ID: 26303008
[TBL] [Abstract][Full Text] [Related]
8. HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies.
Fenner L; Atkinson A; Boulle A; Fox MP; Prozesky H; Zürcher K; Ballif M; Furrer H; Zwahlen M; Davies MA; Egger M;
J Int AIDS Soc; 2017 Jun; 20(1):21327. PubMed ID: 28691438
[TBL] [Abstract][Full Text] [Related]
9. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
Manasa J; Lessells RJ; Skingsley A; Naidu KK; Newell ML; McGrath N; de Oliveira T;
PLoS One; 2013; 8(8):e72152. PubMed ID: 23991055
[TBL] [Abstract][Full Text] [Related]
10. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
[TBL] [Abstract][Full Text] [Related]
11. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
Wallis CL; Papathanasopolous MA; Fox M; Conradie F; Ive P; Orrell C; Zeinecker J; Sanne I; Wood R; McIntyre J; Stevens W;
Antivir Ther; 2012; 17(2):313-20. PubMed ID: 22293461
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies.
Van Rie A; Westreich D; Sanne I
J Acquir Immune Defic Syndr; 2011 Apr; 56(4):349-55. PubMed ID: 20926954
[TBL] [Abstract][Full Text] [Related]
13. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.
Gupta A; Wood R; Kaplan R; Bekker LG; Lawn SD
PLoS One; 2012; 7(3):e34156. PubMed ID: 22479548
[TBL] [Abstract][Full Text] [Related]
14. Determinant factors for the occurrence of tuberculosis after initiation of antiretroviral treatment among adult patients living with HIV at Dessie Referral Hospital, South Wollo, Northeast Ethiopia, 2020. A case-control study.
Abdu M; Ali Y; Anteneh S; Yesuf M; Birhanu A; Mohamed S; Hussien A
PLoS One; 2021; 16(3):e0248490. PubMed ID: 33724992
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of current haemoglobin levels for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort study.
Kerkhoff AD; Wood R; Cobelens FG; Gupta-Wright A; Bekker LG; Lawn SD
BMC Med; 2015 Apr; 13():70. PubMed ID: 25889688
[TBL] [Abstract][Full Text] [Related]
16. Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
Cuong DD; Sönnerborg A; Van Tam V; El-Khatib Z; Santacatterina M; Marrone G; Chuc NT; Diwan V; Thorson A; Le NK; An PN; Larsson M
BMC Infect Dis; 2016 Dec; 16(1):759. PubMed ID: 27986077
[TBL] [Abstract][Full Text] [Related]
17. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B
Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886
[TBL] [Abstract][Full Text] [Related]
18. Development of tuberculosis in human immunodeficiency virus infected patients receiving antiretroviral therapy.
Martín-Echevarria E; Serrano-Villar S; Sainz T; Moreno A; Casado JL; Dronda F; Elías MJ; Navas E; Zapata MR; Moreno S
Int J Tuberc Lung Dis; 2014 Sep; 18(9):1080-4. PubMed ID: 25189556
[TBL] [Abstract][Full Text] [Related]
19. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting.
Badri M; Lawn SD; Wood R
BMC Infect Dis; 2008 Jul; 8():89. PubMed ID: 18601727
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
